Your browser doesn't support javascript.
loading
Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independent of obesity.
Scott, Robert A; Fall, Tove; Pasko, Dorota; Barker, Adam; Sharp, Stephen J; Arriola, Larraitz; Balkau, Beverley; Barricarte, Aurelio; Barroso, Inês; Boeing, Heiner; Clavel-Chapelon, Françoise; Crowe, Francesca L; Dekker, Jacqueline M; Fagherazzi, Guy; Ferrannini, Ele; Forouhi, Nita G; Franks, Paul W; Gavrila, Diana; Giedraitis, Vilmantas; Grioni, Sara; Groop, Leif C; Kaaks, Rudolf; Key, Timothy J; Kühn, Tilman; Lotta, Luca A; Nilsson, Peter M; Overvad, Kim; Palli, Domenico; Panico, Salvatore; Quirós, J Ramón; Rolandsson, Olov; Roswall, Nina; Sacerdote, Carlotta; Sala, Núria; Sánchez, María-José; Schulze, Matthias B; Siddiq, Afshan; Slimani, Nadia; Sluijs, Ivonne; Spijkerman, Annemieke Mw; Tjonneland, Anne; Tumino, Rosario; van der A, Daphne L; Yaghootkar, Hanieh; McCarthy, Mark I; Semple, Robert K; Riboli, Elio; Walker, Mark; Ingelsson, Erik; Frayling, Tim M.
Afiliação
  • Scott RA; MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom.
  • Fall T; Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Pasko D; Genetics of Complex Traits, University of Exeter Medical School, Exeter, UK.
  • Barker A; MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom.
  • Sharp SJ; MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom.
  • Arriola L; Public Health Division of Gipuzkoa, San Sebastian, Spain.
  • Balkau B; Instituto BIO-Donostia, Basque Government, San Sebastian, Spain.
  • Barricarte A; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.
  • Barroso I; Inserm, CESP, U1018, Villejuif, France.
  • Boeing H; Univ Paris-Sud, UMRS 1018, Villejuif, France.
  • Clavel-Chapelon F; Navarre Public Health Institute (ISPN), Pamplona, Spain.
  • Crowe FL; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.
  • Dekker JM; The Wellcome Trust Sanger Institute, Cambridge, United Kingdom.
  • Fagherazzi G; University of Cambridge Metabolic Research Laboratories, Cambridge, UK.
  • Ferrannini E; German Institute of Human Nutrition Potsdam-Rehbruecke, Germany.
  • Forouhi NG; Inserm, CESP, U1018, Villejuif, France.
  • Franks PW; Univ Paris-Sud, UMRS 1018, Villejuif, France.
  • Gavrila D; University of Oxford, United Kingdom.
  • Giedraitis V; Department of Epidemiology and Biostatistics, VrijeUniversiteit Medical Center, Amsterdam, The Netherlands.
  • Grioni S; Inserm, CESP, U1018, Villejuif, France.
  • Groop LC; Univ Paris-Sud, UMRS 1018, Villejuif, France.
  • Kaaks R; Department of Internal Medicine, University of Pisa, Pisa, Italy.
  • Key TJ; MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom.
  • Kühn T; Lund University, Malmö, Sweden.
  • Lotta LA; Umeå University, Umeå, Sweden.
  • Nilsson PM; Department of Epidemiology, Murcia Regional Health Council, Murcia, Spain.
  • Overvad K; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.
  • Palli D; Department of Public Health and Caring Sciences, Geriatrics, Uppsala University Sweden.
  • Panico S; Epidemiology and Prevention Unit, Milan, Italy.
  • Quirós JR; University Hospital Scania, Malmö, Sweden.
  • Rolandsson O; Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland.
  • Roswall N; German Cancer Research Centre (DKFZ), Heidelberg, Germany.
  • Sacerdote C; University of Oxford, United Kingdom.
  • Sala N; German Cancer Research Centre (DKFZ), Heidelberg, Germany.
  • Sánchez MJ; MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom.
  • Schulze MB; Lund University, Malmö, Sweden.
  • Siddiq A; Department of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark.
  • Slimani N; Aalborg University Hospital, Aalborg, Denmark.
  • Sluijs I; Cancer Research and Prevention Institute (ISPO), Florence, Italy.
  • Spijkerman AM; Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy.
  • Tjonneland A; Public Health Directorate, Asturias, Spain.
  • Tumino R; Umeå University, Umeå, Sweden.
  • van der A DL; Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Yaghootkar H; Unit of Cancer Epidemiology, Citta' della Salute e della Scienza Hospital-University of Turin and Center for Cancer Prevention (CPO), Torino, Italy.
  • McCarthy MI; Andalusian School of Public Health, Granada, Spain.
  • Semple RK; CIBER Epidemiología y Salud Pública (CIBERESP), Spain.
  • Riboli E; Instituto de Investigación Biosanitaria de Granada (Granada.ibs), Granada (Spain).
  • Walker M; German Institute of Human Nutrition Potsdam-Rehbruecke, Germany.
  • Ingelsson E; School of Public Health, Imperial College London, UK.
  • Frayling TM; International Agency for Research on Cancer, Lyon, France.
Diabetes ; 63(12): 4378-4387, 2014 Dec.
Article em En | MEDLINE | ID: mdl-24947364
ABSTRACT
We aimed to validate genetic variants as instruments for insulin resistance and secretion, to characterize their association with intermediate phenotypes, and to investigate their role in type 2 diabetes (T2D) risk among normal-weight, overweight, and obese individuals. We investigated the association of genetic scores with euglycemic-hyperinsulinemic clamp- and oral glucose tolerance test-based measures of insulin resistance and secretion and a range of metabolic measures in up to 18,565 individuals. We also studied their association with T2D risk among normal-weight, overweight, and obese individuals in up to 8,124 incident T2D cases. The insulin resistance score was associated with lower insulin sensitivity measured by M/I value (ß in SDs per allele [95% CI], -0.03 [-0.04, -0.01]; P = 0.004). This score was associated with lower BMI (-0.01 [-0.01, -0.0]; P = 0.02) and gluteofemoral fat mass (-0.03 [-0.05, -0.02; P = 1.4 × 10(-6)) and with higher alanine transaminase (0.02 [0.01, 0.03]; P = 0.002) and γ-glutamyl transferase (0.02 [0.01, 0.03]; P = 0.001). While the secretion score had a stronger association with T2D in leaner individuals (Pinteraction = 0.001), we saw no difference in the association of the insulin resistance score with T2D among BMI or waist strata (Pinteraction > 0.31). While insulin resistance is often considered secondary to obesity, the association of the insulin resistance score with lower BMI and adiposity and with incident T2D even among individuals of normal weight highlights the role of insulin resistance and ectopic fat distribution in T2D, independently of body size.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Composição Corporal / Resistência à Insulina / Diabetes Mellitus Tipo 2 / Insulina / Obesidade Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Composição Corporal / Resistência à Insulina / Diabetes Mellitus Tipo 2 / Insulina / Obesidade Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Reino Unido